Validating RSK as a molecular target for the treatment of cancer

Relapses in cancer usually result in the tumour becoming resistant to chemotherapy. This leaves a treatment gap that needs to be filled for these patients. One such cancer is triple negative breast cancer, this type of breast cancer is very aggressive with a high death rate. Dr. Sandra Dunn’s research group want to find new […]

Read More
Exploring the potential of chemical suppressors of nonsense mutations for treatment of multiple genetic disorders

Over 5000 rare genetic diseases collectively affect 1 in 12 Canadians. For these disorders about 10% of patients share a common mutation type that introduces a premature termination codon (PTC) in the gene and results in truncated and non-functional protein. The previously found PTC suppressors have limited effect or unacceptable side effects. The goal of […]

Read More
Somatostatin signalling and diabetes

The prevalence of diabetes is growing rapidly and currently, over 60 million people worldwide use insulin treatment to manage their diabetes. However, insulin treatment can result in hypoglycemia or low blood sugar levels. To date only retroactive treatments are available to treat hypoglycemia, which affects an individual’s quality of life and increases the likelihood of […]

Read More